drugset / Trial / NCT03413358

Clinical Trial for Post-marketing Evaluation of Sheng Bai Oral Liquid

NCT03413358

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the efficacy and safety of Sheng Bai oral liquid in prevention and treatment of the decrease of neutrophilics after chemotherapy in patients with non-small-cell lung cancer.

Timeline

Start
2018-01-15
Primary completion
2019-10-31
Completion
2019-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Sheng Bai oral liquid Unknown 40 ml Oral
Background Carboplatin Small molecule
Background Cisplatin Other / unclassified